ENTL Entelos Regs

    


Entelos Inc.



                                  ENTELOS, Inc.

                          ("Entelos" or "the Company")

                         Appointment of NOMAD and Broker

Entelos, Inc. (LSE:ENTL), a leading life sciences company building predictive
computer models of human physiology and "virtual patients" for drug discovery
and development, is pleased to announce the appointment of KBC Peel Hunt Ltd as
its NOMAD and Corporate Broker with immediate effect.

Enquiries

Entelos, Inc.
Alan Blazei, Chief Financial Officer                 Tel: +1 650 572 5400
Jill Fujisaki, Vice President, Investor Relations
KBC Peel Hunt
Capel Irwin                                          Tel: +44 (0)20 7418 8900
Buchanan Communications
Lisa Baderoon/Mary-Jane Johnson                      Tel: +44 (0)20 7466 5000

About Entelos, Inc.

Entelos, Inc. (www.entelos.com) is a US-based life sciences company applying
next-generation predictive technologies to revolutionize the way medicines are
discovered, developed, and utilized. The Company leverages its proprietary in
silico disease models, "virtual patients", and toxicology reference systems to
develop safer and more effective drugs and support pharmaceutical R&D and
commercialization. In addition to internal drug programs in rheumatoid arthritis
and women's health, Entelos provides customized technology and research services
to global pharmaceutical and health-care companies in cardiovascular diseases,
asthma, obesity, diabetes, hematopoeisis (anemia), cholesterol metabolism, and
skin sensitization. The Company is also developing a model in oncology and is
collaborating with the FDA to build a model of drug-induced liver injury.
Entelos also offers cost-effective drug development capabilities through its
strategic alliance with India-based Jubilant Biosys Ltd.

Entelos Regs (LSE:ENTL)
Historical Stock Chart
From Jun 2024 to Jul 2024

Entelos Regs (LSE:ENTL)
Historical Stock Chart
From Jul 2023 to Jul 2024